Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
* j* U7 O( [7 F! J7 I$ z. c: j
0 N6 X4 T# @ J0 x3 n3 z
1 o' H* Y( G$ |* ~% cSub-category:
1 {' @3 \! }/ r% @! ]Molecular Targets
/ L4 Z0 m: l8 Z" v5 u6 f. ? T+ I8 ~
( T% c( ?, a& p9 Q( C) N/ d4 ~Category:1 } ]$ Q# e3 j8 d
Tumor Biology
1 E( S* p9 @, c* Z4 T2 S! n5 e3 h, Y) d- ~' p# l5 t* Y! G
) p K8 {& W+ T8 w: ~
Meeting:3 _. a! x7 ], ~/ C' ^4 [. S: D; @8 G2 }
2011 ASCO Annual Meeting 3 g N8 M) m7 j$ f
6 f/ V: B! K. d2 u% J( S' N8 ~5 |* [% o0 D6 I
Session Type and Session Title:
. Q. q5 I }9 {Poster Discussion Session, Tumor Biology
! M' L8 b( F( `# J4 R
9 o: K( {; _* N; f- t& ]& P
) [: I$ H4 W* I) T& r0 j6 rAbstract No:% D! c4 z! t* U# @
10517
: ?3 N% P1 r5 W& t% s) i& V. ^5 ^# s0 \2 Y/ u
6 G( k8 l8 T% {7 J1 R
Citation:
- d3 s4 m4 q0 A: z ]# T' SJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' V2 i0 ~2 |* M% y- n& X1 g _% s- n4 @2 b# b$ n7 s
3 J3 M# m9 J2 ^4 o( Q/ SAuthor(s):
# [/ C! M( z3 F" r/ c! x; kJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
% V- G6 q, y" t2 X1 `" ?7 q- f0 ~1 Z$ } t' W
& B& L( F, Z R2 ]
# H/ G3 R# L5 [6 o, |! l+ m
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' \! x6 ~' @2 a( {% u7 Z. A: S5 t
, G. J9 J# w( x! l
Abstract Disclosures
; } _5 X" O( i0 ~- B! q7 n% u. ?" R4 l7 B+ v4 C" N: ?5 N
Abstract:0 t" k8 L5 F% b1 e. e
, l6 _5 @, T+ m3 V- e Q0 {4 ~% I4 ~' }( M# k
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.9 Q+ _! p) Z$ }1 s) ~ w7 u$ C
7 d% D4 g' ^) j5 ? 3 u, k) k- v* T8 O
|
5 {: }: Q2 z! h* ^- Y) l
显身卡
